To advance the science of tobacco control, an enhanced understanding of the bio-behavioral basis of nicotine addiction is needed. In this study, we provide an overview of data from investigations of genetic factors in smoking behavior, discuss potential bio-behavioral mechanisms and effect modifiers, and suggest avenues for pharmacogenetics research in the area of smoking cessation treatment. The evidence to date is very consistent with respect to the significance of genetic contributions to smoking behavior. However, attempts to elucidate the role of specific genetic variants have met with mixed success. Explanations for the lack of consistency in the results of genetic association studies include biases in ascertainment, ethnic admixture, lack of attention to covariates or modifiers of genetic risk, and the need for more refined phenotypes. As the field of genetics and smoking research progresses, increasing attention is being devoted to gene -environment interactions, with particular attention to the identification of genetic variants that may modify the effects of pharmacological treatment for smoking. With advances in molecular biology and genomics technology, individualized tailoring of smoking cessation therapy to genotype is within our grasp. Such research has the potential to improve treatment outcome, thereby reducing morbidity and mortality from smoking-related disease.
Introduction
Research on tobacco use and smoking cessation has contributed to reductions in smoking prevalence, yet, about 25% of American adults continue to smoke, despite widespread knowledge of tobacco's harmful effects (Centers for Disease Control, 2000) . In order to make greater progress in tobacco control, more attention is being devoted to understanding the biobehavioral basis of nicotine dependence. With advances in molecular biology and genomics technology, it is now possible to identify the specific genes that may contribute to smoking initiation, nicotine dependence, and therapeutic response to smoking treatments. In this paper, we present a brief overview of available data on genetics and smoking behavior, using the Biobehavioral Model of smoking behavior as a framework. In addition, we review what is known about the efficacy of different smoking cessation treatments and discuss how genetics research can be applied to improve treatment outcome.
Bio-behavioral model of smoking behavior
The Bio-behavioral model is a framework for examining the determinants health-related behaviors that contribute to disease susceptibility (Hiatt and Rimer, 1999) . The model was originally applied to tobacco use by the NCI Tobacco Research Implementation Group (TRIP, 1998) and has been adapted further to highlight three fundamental premises of genetics research on smoking behavior (Figure 1) . First, genetic factors play an important role in smoking behavior. As will be discussed below, there are abundant data to support the premise that smoking initiation and persistence are heritable . Emerging evidence has pointed to genes important in the different catecholamine pathways and genes that influence responses to the drug, nicotine (Arinami et al., 2000; Walton et al., 2001) .
Second, these genetic influences on smoking are mediated, in part, by individual differences in biologically-based behavioral and personality traits as well as differences in the reinforcing properties of nicotine. The potential mechanisms of genetic effects are being studied in both laboratory experiments (e.g., examining neural responses to nicotine) and in prospective studies in the naturalistic environment.
Third, genetic influences occur in the context of key psychological and social influences, including depression, race, gender, and tobacco advertising. Each of these principals, and supporting data, are discussed in the following sections.
Overview of genes and smoking behaviors
Abundant data from twin studies provide evidence for the heritability of cigarette smoking. Such studies compare the concordance rate for a smoking trait in monozygotic twins to that in dizygotic twins. Using the Australian twin registry, Heath and Martin (1993) found that inherited factors accounted for 53% of the variance in smoking practices. More recent data from True et al. (1999) and Kendler et al. (1999) suggest that the heritability of a diagnosis of nicotine dependence is even higher. Sullivan and Kendler (1999) summarized data from a large number of twin studies indicating that additive genetic effects account for 56% of the variance in smoking initiation, and 67% of the variance in nicotine dependence. Significant genetic influences have also been documented for age at smoking onset and for smoking persistence .
While twin studies provide convincing evidence for the heritability of smoking behavior, such studies have not identified the specific genes responsible for these effects. In the search for specific genetic effects on smoking behavior, investigations have focused on two broad classes of genes: (1) those that may predispose to addictive behavior by virtue of their effects on key neurotransmitter pathways (e.g., dopamine, serotonin, and norepinephrine) and (2) genes that may influence response to the drug nicotine (e.g., nicotinic receptors, nicotine metabolism).
The dopamine D2 receptor (DRD2) gene has been studied most extensively with respect to its role in addictive behaviors. In a series of studies, the more rare A1 (or B1) allele has been associated with propensity to alcoholism, obesity, and compulsive gambling, as well as with a variety of neuropsychiatric conditions (Noble, 2000) . However, these results have not been replicated in all cases (Bierut et al., 2000) . Because of its effects on a broad range of addictive behaviors, DRD2 has been termed a 'reward gene' (Comings et al., 1996; Noble et al., 1994) . Specifically, it is speculated that individuals with the A1 allele have a deficit in dopamine regulation, and therefore, may find greater reinforcement in substances and behaviors that increase dopamine transmission. In support of this hypothesis are data showing that individuals who are homozygous or heterozygous for the A1 allele have a reduced density of D2 receptors in the brain (Noble et al., 1994) .
DRD2 is an ideal candidate gene for smoking related research, because of nicotine's effects on the dopamine reward pathway (Dani and Heinemann, 1996) . Three studies found a higher prevalence of the more rare A1 or B1 allele of the dopamine 2 receptor (DRD2) gene among smokers than among non-smokers (Comings et al., 1996; Noble et al., 1994; Spitz et al., 1998) . However, a small family-based analysis (Bierut et al., 2000) did not provide evidence for significant linkage of smoking to the DRD2 locus. In a case -control study of smokers and non-smokers, Lerman et al. (1999) found that DRD2 interacted with the dopamine transporter (DAT) gene in its effects on smoking behavior. The DAT polymorphism is of particular interest because the 9-repeat allele has been associated with a 22% reduction in dopamine transporter protein (Heinz et al., 2000) . Since a reduction in dopamine transporter level would result in less clearance and greater bio-availability of dopamine, it is speculated that individuals who have the 9-repeat allele may have less need to use nicotine to stimulate dopamine activity. The association of the DAT gene with smoking behavior has been supported in one study (Sabol et al., 1999) , but not replicated in two other studies (Jorm et al., 2000; Vandenbergh et al., 2002) . Thus, the role of DAT in smoking behavior remains unclear. The DRD4 gene, while not associated with smoking behavior in a case -control analysis, was related to smoking patterns among smokers with depression . Further, in a small sample of African Americans, DRD4 genotype predicted smoking cessation .
The serotonin pathway is also under investigation in genetic studies of smoking because of serotonin's role in depression and anxiety, two traits linked with smoking behavior Gilbert and Gilbert, 1995) . Candidate polymorphisms include those in genes that are involved in serotonin biosynthesis (e.g., tryptophan hydroxylase, TPH) and serotonin reuptake (serotonin transporter, 5HTTLPR). Two recent studies have shown that individuals who are homozygous for the more rare A allele of TPH are more likely to initiate smoking, and start smoking at an earlier age (Lerman et al., 2001; Sullivan et al., 2001) . Although the 5HTTLPR was not associated with smoking status , there is evidence from two studies that this polymorphism modifies the effect of anxiety-related traits on smoking behavior (Hu et al., 2000; Lerman et al., 2000) . With regard to the norepinephrine pathways, a recent study found that the amount of cigarette consumption was associated with polymorphisms in the genes for monoamine oxidase (MAO-A) and dopamine beta hydroxylase (DBH) (McKinney et al., 2000) .
Genes involved in the metabolism of nicotine are biologically plausible candidates for genetic studies of smoking behavior. One hypothesis is that slower metabolizers of nicotine may be less prone to initiate smoking because they may experience more aversive effects (Pianezza et al., 1998) . Once smoking is initiated, it is thought that slower metabolizers would require fewer cigarettes to maintain nicotine titers at an optimal level. Initial support for this premise was provided in a study of the P450 CYP2A6 gene (Pianezza et al., 1998) which encodes the key enzyme Genetics and nicotine dependence treatment C Lerman and R Niaura involved in metabolism of nicotine to inactive cotinine. Later studies, however, did not support this finding and suggested that the CYP2A6 variant is much more rare than originally reported (London et al., 1999; Oscarson et al., 1998) .
Although genes regulating nicotine receptor function would be prime candidates for smoking risk, data on functional genetic variation in humans are not yet available. In a recent study of the B2 nicotinic receptor, four single neucleotide polymorphisms (of unknown functional significance) were identified, but none of these was associated with smoking behavior (Silverman et al., 2000) .
One contributing factor to the lack of replication in genetic studies of smoking behavior has been the reliance on case -control (association) data (Sullivan et al., 2001 ). In case -control studies, there is the possibility of population stratification due to the fact that cases (smokers) and controls (non-smokers) may have been drawn from populations with different ethnicities. Since the frequencies of these polymorphisms may differ in different ethnic groups (e.g., Irish vs Italian), and because ethnic/cultural factors may influence smoking practices, ethnic admixture can bias case -control studies. While it has been suggested that the extent of bias due to population stratification in cancer research is minimal (Wacholder et al., 2000) , it is not yet known to what extent this problem leads to false positive results in studies of smoking or other behavioral traits. A second limitation of previous research has been the reliance on more crude assessments of smoking status (e.g., smoker vs non-smoker). Since complex traits such as smoking are likely caused by multiple genes acting in conjunction with environmental factors, it is critical that the phenotypes for smoking be well-defined. Such phenotypes include persistence of smoking and difficulty quitting, signs and symptoms of nicotine dependence, and lifetime trajectories of tobacco use and development dependence.
Bio-behavioral mechanisms of genetic effects

Heritable behavioral traits
Genetic polymorphisms that affect neurotransmitter systems can have wide ranging effects on behavior. Thus, it has been hypothesized that heritable personality or behavior traits are one mechanism linking genetic variants to smoking behavior (Hughes, 1986) .
Novelty seeking is a temperamental trait characterized by impulsivity, stimulation-seeking, and sensitivity to reward or reinforcement; it is thought to be modulated by dopaminergic mechanisms (Cloninger, 1987 (Cloninger, , 1994 Cloninger et al., 1993) . This personality dimension is associated with tobacco use during adolescence (Wills et al., 1994) , early onset of smoking in adolescent boys (Masse and Tremblay, 1997) , and nicotine dependence in adults (Pomerleau et al., 1992) . Twin studies have also provided evidence for significant genetic contributions to novelty seeking (Heath et al., 1994; Stallings et al., 1996) . Molecular genetic studies have related novelty seeking with genetic variants of the DRD4 and DRD2 genes Ebstein et al., 1997; Noble et al., 1998) . However, two studies have not supported such association (Malhotra et al., 1996; Vandenbergh et al., 1997) . With regard to dopamine transporter gene variants, smokers with DAT-9 alleles were found to score lower on novelty seeking than those with other DAT genotypes (Sabol et al., 1999) . Further, Sabol et al. (1999) found that former smokers had significantly lower novelty seeking scores than current smokers, suggesting a role for this personality trait in smoking cessation. Based on these data, it is plausible that the effects of dopamine gene variants on nicotine dependence may be partially mediated by novelty seeking personality traits.
There is also evidence to suggest that hostility or anxiety-related traits might mediate the influence of serotonergic gene variants on smoking behavior (Gilbert and Gilbert, 1995) . A genetic variant of the serotonin transporter gene (5-HTTLPR S allele) has been associated with anxiety-related traits (e.g., harm avoidance) (Lesch et al., 1996) . However, this has been disputed in recent studies . The tryptophan hydroxylase gene, which codes for a rate limiting enzyme in serotonin biosynthesis, has also been related to hostile aggression and poor impulse control Nielsen et al., 1994) . Hostility, in turn, has also been shown to predict smoking status in a 20-year follow-up of participants from the UNC Alumni Heart Study (Lipkus et al., 1994) . Thus, harm avoidance and hostility may also mediate the effects of serotonergic gene variants on smoking practices.
Reinforcing properties of nicotine
While genes involved in neurotransmitter systems may increase susceptibility to addiction (including tobacco use) via their effects on biologically-based personality traits, genetic effects that are specific to nicotine may act by altering the reinforcing properties of this drug. While this hypothesis has yet to be tested, existing data on the rewarding effects of nicotine suggest that this is a biologically plausible mechanism.
Nicotine has both positive reinforcing effects (e.g., enhances alertness, arousal, pleasure) and negative reinforcing effects (relieves adverse mood and withdrawal symptoms). Individual differences in the rewarding effects of the initial dose of nicotine from a cigarette may account for the observation that some young adults become dependent smokers, while others can experiment and not progress to nicotine dependence (Eissenberg and Balster, 2000; Flay et al., 1983) . In support of this hypothesis, one cross-sectional analysis found that pleasant emotional and physiological effects of the initial smoking experience discriminated teens who continued to experiment with cigarettes and those who did not (Friedman et al., 1985) . Among adults, retrospective reports of the rewarding effects of the initial smoking experience (e.g., pleasurable rush or buzz, relaxation) were associated with current levels of nicotine dependence (Pomerleau, 1998) . These findings were replicated recently in a sample of college-age women (Pomerleau et al., 1999) .
Genetic variants encoding for nicotonic receptors and those affecting the metabolism of nicotine could potentially alter the reinforcing properties of nicotine, thereby influencing smoking initiation and persistence. This hypothesis is being tested in ongoing experiments that compare subjective, psychophysiological, and neural responses to nicotine (and smoking abstinence) in a controlled laboratory setting.
Covariates in genetics research on smoking
In accordance with the Bio-behavioral model, future research on genetics and smoking must take into account the psychological and socio-environmental factors that may modify genetic risk. Below, we discuss relevant studies that point to key covariates for genetics research.
Psychological
factors A significant association between major depressive disorder (MDD) and cigarette smoking has been reported. Compared to neversmokers, smokers demonstrate over twice the lifetime prevalence of MDD (Breslau et al., 1991) . Comorbidity between MDD and smoking remains strong even when controlling for age, ethnicity, educational level, and degree of nicotine dependence (Breslau et al., 1998; Killen et al., 1996; Perez-Stable et al., 1990; Son et al., 1997) . Prevalence of smoking also increases according to levels of current symptoms of depression (Anda et al., 1990) , and smoking cessation relapse is associated with increased symptoms of depression ). History or current symptoms of MDD may interfere with smoking cessation because of increases in dysphoria and withdrawal symptoms following attempts to quit smoking (Hall et al., 1996) , or relapse to depression following some period of smoking abstinence (Borrelli et al., 1996; Glassman et al., 2001) .
In addition to MDD, tobacco use is associated with other psychiatric comorbidities, including alcohol and other substance abuse and dependence, attention deficit and hyperactive disorder, and schizophrenia (Kandel et al., 2001) . A population-based study estimated that 41% of persons suffering from current mental illness were smokers, and that over 40% of the tobacco in the US is consumed by persons with a comorbid psychiatric disorder (Lasser et al., 2000) . An important issue for further research is determining which smokers rely on tobacco and nicotine to redress symptoms of comorbid psychiatric disorders, a vulnerability that may be influenced to some unknown degree by genetic factors. This knowledge might then be used to adapt existing or develop new interventions targeted to the needs of these subgroups. For example, can pharmacologic treatments be developed that serve a function similar to the effects of smoking, thereby decreasing dependence on tobacco and nicotine and increasing the likelihood of cessation?
Socio-Environmental factors Gender and racial differences in smoking status and smoking cessation have been documented and are of potential importance in investigations of the role of genetic factors in smoking behavior. With regard to race, the prevalence of smoking in Caucasians and African Americans is comparable (about 25%), while Native Americans have a higher prevalence (40%) and Hispanics and Asians have a lower smoking prevalence (19 and 14%, respectively) (Centers for Disease Control, 2000) . Despite similarities in smoking prevalence among African Americans and Caucasians, there are some notable differences in smoking behaviors. African Americans initiate habitual smoking at a later age, report smoking fewer cigarettes, but smoke cigarettes with higher nicotine and tar content (King, 1997; King et al., 1997; Nelson et al., 1995) . In addition, although African Americans are more likely than Caucasians to report having made a quit attempt for at least 24 h in the past year, they are less likely to have sustained abstinence (USDHHS, 1998). Reasons cited for the lower probability of smoking abstinence among African Americans include less use of NRT (Piper et al., 2001) , the absence of culturally tailored smoking cessation interventions (Voorhees et al., 1996) , targeted tobacco industry advertizing (Pierce et al., 1999) , and faster rates of nicotine metabolism (Caraballo et al., 1998) . Of particular relevance to genetics research, African Americans have been shown to have a higher prevalence of the putative risk alleles for smoking (Lerman et al., 1999) ; however, the significance of this fact for smoking cessation has yet to be determined.
Recent population data also indicate that until recently, more men than women were current smokers (28 vs 22%), but the ratio of former smokers to current smokers is consistently lower for women than for men (47 vs 52%) (Perkins et al., 2001; Centers for Disease Control, 1994) . Smoking cessation clinical trials have also demonstrated that women are less likely to quit smoking than men following behavioral counseling (Ockene, 1993) and NRT (Wetter et al., 1999; Royce et al., 1997) . Relapse rates following cessation have also been shown to be higher for women than for men across multiple modes of treatment (Stapleton et al., 1995; Davis and Ramos, 1999) . Potential explanations for the lower success rates among women include greater concerns about abstinence-induced weight gain (Pirie et al., 1992) , greater reactivity to smoking-related cues (Perkins, 1996 (Perkins, , 2001 , less sensitivity to the biological effects of nicotine and NRT (Perkins, 1999) , and higher levels of depression symptoms that contribute to relapse (Borelli et al., 1996) .
Several environmental factors contribute to smoking initiation, although the effects on smoking persistence are unknown. For example, family and peer smoking behaviors are associated with smoking experimentation and progression to more habitual smoking among adolescents (Chassin et al., 1986; Choi et al., 1997; Conrad et al., 1992) . The link between tobacco industry advertising and youth smoking is also well established (Evans et al., 1995; Pierce et al., 1991) . In fact, there is a dose-response relationship between the number of cigarette promotional items owned by adolescents and their smoking behavior (Sargent et al., 2000) . Among young adults, tobacco use is positively associated with participation in social activities, whereas religion, educational achievement, and athletic participation have protective effects (Rigotti et al., 2000) .
With regard to smoking cessation, exposure to environmental smoking-related cues may play an important role in promoting relapse. Moreover, individual differences in response to environmental cues to smoke (e.g., the sight or smell of a lit cigarette) may be genetically mediated. Dopaminergic activity has been implicated in cue-elicited craving. In a recent study, the DRD4 VNTR polymorphism, which putatively expresses functional differences in dopamine (D4) receptors, was examined in association with cue-elicited craving for tobacco (Hutchison et al., 2002) . Participants who were homozygous or heterozygous for the seven repeat (or longer) allele demonstrated significantly higher craving, more arousal, less positive affect, and more attention to the smoking cues than did the participants absent in this polymorphism.
To date, there has been a paucity of studies examining gene-environment interactions in smoking behavior or response to treatment. As will be discussed below, pharmacogenetic studies of smoking cessation provide an ideal model to test hypotheses about geneenvironment interactions.
Overview of smoking cessation treatments
Non-pharmacologic treatment About 90% of successful quitters and 80% of unsuccessful quitters quit on their own rather than within an organized smoking cessation program (Fiore et al., 1990) . The preference for self-quitting methods, coupled with the need to improve the success of these self-quitters, has promoted the use of minimal contact smoking cessation interventions. Standard minimal contact smoking cessation interventions have produced 12-month quit rates of 14% (Cohen et al., 1989) . Brief telephone counseling has been shown to significantly increase long-term quit rates to 20 -25% (Lando et al., 1996; Orleans et al., 1991) to approximate the quit rates of more intensive treatments.
Nicotine replacement therapies It is now well established that nicotine replacement therapy (NRT) can increase smoking cessation rates significantly compared to behavioral counseling Tang et al., 1994) . Thus, NRT is now considered standard care for smoking cessation (Fiore, 2000) . However, nicotine gum has not been found to be effective across all settings, and it often is not used properly (AHCPR, Cepeda-Benito, 1993; Fiore et al., 1992) . Thus, the transdermal nicotine (TN) patch has been recommended as the preferred NRT for clinical use (Fiore, 2000) . A meta-analysis found overall 6-month quit rates of 22% for TN vs 9% for placebo .
While TN is significantly more effective than placebo or behavioral counseling alone, the majority of smokers (70 -80%) do not quit with this method Jorenby et al., 1995; Transdermal Nicotine Study Group, 1991) . The limited success of TN has been attributed by some to inadequate nicotine replacement with the standard clinical dose of 21 mg (Dale et al., 1995) . Although one trial showed a significant increase in quit rates with a 44 mg dose, this effect was not maintained by 12-month follow-up (Dale et al., 1995) . Other studies have not found significant dose response effects, even in the short term Jorenby et al., 1995; Paoletti et al., 1996) . Furthermore, measures of nicotine dependence (e.g., blood nicotine/cotinine, Fagerstrom questionnaire) do not strongly predict quit rates from TN treatment in most studies (Kenford et al., 1994; Transdermal Nicotine Study Group, 1991) .
The limited efficacy of TN for some smokers may be attributable, in part, to its pharmacokinetic profile. Following administration of TN, venous levels of nicotine increase slowly and then plateau within 4 -6 h (Henningfield and Keenan, 1993) . This profile is designed to alleviate symptoms of withdrawal from abstinence (Hughes, 1993) . Smokers receiving TN report significantly lower levels of withdrawal symptoms than those receiving placebo (Dale et al., 1995; Fiore et al., 1994; Transdermal Nicotine Study Group, 1991) . However, TN's kinetic profile is also designed to minimize positive reinforcement from nicotine (Henningfield, 1995) . Specifically, the slow nicotine delivery and stable levels of plasma nicotine result in desensitization of nicotine receptors and tolerance to nicotine's reinforcing effects (Benowitz, 1996; Henningfield, 1995) . This is consistent with evidence that TN does not completely alleviate craving for cigarettes (Paoletti et al., 1996; Pickworth et al., 1996) .
These results with TN have led to the development of alternative forms of NRT which more closely resemble cigarette smoking in terms of nicotine delivery. The nicotine (pulmonary) inhaler has been shown to be effective in recent trials (Silagy et al., 1994) . However, there are a number of limitations to this approach, including difficulties in inhaling deeply enough to obtain sufficient nicotine levels, inability to define a precise dose, and slower and lower peaks of nicotine delivery (Tonnesen et al., 1993) . A promising method is the nicotine nasal spray (NS). This method results in more rapid peak increases in blood nicotine and absorption in the brain, similar to the effects of cigarette smoking (Henningfield and Keenan, 1993) . Four placebo controlled clinical trials of NS have demonstrated quit rates comparable to TN (Blondal et al., 1997; Hjalmarson et al., 1994; Schneider et al., 1995; Sutherland et al., 1992) . In a meta analysis, the quitting odds ratio for NS vs placebo was 2.9, compared with 2.1 for TN vs placebo (Silagy et al., 1994) . A recent randomized trial comparing TN to TN+NS found the combination superior to TN alone (Blondal et al., 1999) . However, 6-month abstinence rates reported for TN+NS (31%) are no higher than those reported previously for NS alone (44%, Hjalmarson et al., 1994 26% Sutherland et al., 1992 .
Smokers' experiences of positive reinforcement from nicotine may influence their success with the different nicotine replacement products. TN and NS differ markedly in nicotine delivery and kinetics, resulting in differences in reinforcing effects. TN delivers nicotine slowly and maintains stable nicotine levels; this profile relieves withdrawal symptoms (negative reinforcement) (Henningfield, 1995; Hughes, 1993) . However, this process also facilitates tolerance to nicotine's effects and minimizes its positive reinforcing value (Benowitz, 1996) . By contrast, NS results in rapid absorption of nicotine in the brain and more variability in nicotine levels; this profile enhances its positive reinforcing effects (in addition to providing relief from withdrawal) (Henningfield and Keenan, 1993; Schneider et al., 1996) . Thus, smokers who have a greater preference or need for the positive reinforcing effects of nicotine (e.g., subjective experience of a 'high' or a 'rush'), may respond better to NS than TN. By contrast, smokers who are more prone to experience adverse effects of smoking abstinence may respond better to TN than to NS.
Non-nicotine medications Increasing attention has focused on the efficacy of other pharmacological agents in smoking cessation treatment. Clonidine, initially developed as an antihypertensive drug, has been evaluated as an adjunct to smoking cessation counseling. Recent meta-analyses have concluded that clonidine is an effective smoking cessation aid (Fiore, 2000) ; however, because of significant side effects, clonidine is recommended only as a second-line cessation agent. Buspirone, a non-sedating anxiolytic, has been found to be either not effective, only effective for individuals high in anxiety while taking buspirone, or effective for a short time (Cinciripini et al., 1995; Hilleman et al., 1994; Schneider et al., 1996) . A recent multi-institutional randomized trial (n=989) evaluated the efficacy of fluoxetine hydrochloride, a serotonergic re-uptake inhibitor . Two doses of fluoxetine (30 and 60 mg) were compared to placebo, and all conditions received individualized behavioral counseling. High dose fluoxetine significantly increased cessation rates above the placebo group, but only during the active treatment phase, not a 6-month follow-up.
Bupropion, an antidepressant, appears promising as a pharmacologic smoking cessation treatment. A placebo-controlled randomized trial (n=615) compared three doses of sustained release bupropion (100, 150, or 300 mg/day) to placebo (Hurt et al., 1997) , in the context of brief advise and counseling. At the end of 7 weeks of treatment, 19% of the placebo group, 29% of the 100 mg group, 39% of the 150 mg group, and 44% of the 300 mg group were abstinent. At 1 year, 12% of the placebo group, 20% of the 100 mg group, 23% of the 150 mg group, and 23% of the 300 mg group were abstinent. The cessation rates for the 150 mg and the 300 mg were significantly better than placebo. Bupropion has also been shown to be superior to TN, although the combination of bupropion plus TN was not significantly more effective than bupropion alone . Most recently, long-term (1 year) use of bupropion as a relapse prevention strategy proved superior to placebo during a 1 year mediationfree follow-up interval (Hays et al., 2001) .
The biological mechanisms for bupropion's efficacy have yet to be fully elucidated. However, it is speculated that the dopamine enhancing effects of bupropion may alter the reinforcing value of nicotine, while the noradrenergic activity is thought to affect nicotine withdrawal (Ascher et al., 1995; Balfour, 2001 ). In addition, bupropion appears to reduce the negative mood symptoms associated with smoking abstinence (Shiffman et al., 2000) .
Implications of genetics research for smoking treatment
Genetically-determined differences in preferences for nicotine reinforcement may predict smokers' responsiveness to these alternative NRTs. This hypothesis is being tested in ongoing studies. For example, smokers who carry genetic polymorphisms associated with reduced dopaminergic activity may experience greater benefit from NS than TN because of NS's greater rewarding effects. Alternatively, smokers who have polymorphisms that reduce noradrenergic activity, and who may be more prone to experience withdrawal symptoms, may have better success with TN than with NS.
Additional candidate polymorphisms to examine in clinical trials of NRT are those that encode for enzymes involved in the metabolism of nicotine and those encoding for nicotinic receptors. For example, individual differences in nicotine metabolism rate could alter both the biologically active dose of the drug and the experience of side effects. Thus, genotyping of smokers in treatment could be valuable not only to select the type of NRT, but also to optimize the dosage for a particular smoker.
With regard to non-nicotine medications, ongoing studies are investigating the role of genetic factors in response to bupropion (Zyban 1 ) treatment. Based on the putative mechanism of action (Ascher et al., 1995) , relevant candidate genes are those in the dopamine and norepinephrine pathways (e.g. SLC6A3, DRD2, DRD4, TH, DBH, COMT, MAO-A, MAO-B) . Genes that govern the metabolism of bupropion (e.g., CYP2B6), may also influence the drug's biological activity and side effect profile for individual smokers. Such information would be useful for identifying smokers who are most and least likely to benefit from bupropion and to tailor the dosage to individual smokers.
The potential for genetic modulation of response to treatment is suggested in a recent pilot study. In the context of a bupropion clinical trial, 30 smokers were exposed to smoking cues before the after treatment (David et al., 2001) . Within the bupropion group, subgroup analyses with stratification by genotype demonstrated that following provocative smoking cues, craving was significantly diminished only among subjects with DRD2 A2/A2 genotypes. No reduction was observed in any craving among subjects with DRD2 A1/A1 or A1/A2 genotypes. Thus, individuals with certain polymorphisms may derive greater benefit from treatment with bupropion in terms of cue-elicited craving relief.
Pharmacogenetics, or the application of genetics to tailor pharmacological treatment, is an active area of research in the smoking field. It is an example of a gene-environment interaction, where environment is manipulated by drug treatment (see Figure 2) . The short-term goal of this research is to elucidate the interacting effects of genetic and non-genetic factors in nicotine dependence and to discover the bio-behavioral mechanisms by which genetic variants exert their effects. The ultimate objective is to provide information necessary to improve the efficacy of smoking cessation treatments by individually tailoring treatment to individual smokers' genetic backgrounds.
